These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23539188)

  • 21. Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats.
    Liu X; Cheong J; Ding X; Deshmukh G
    Drug Metab Dispos; 2014 Apr; 42(4):482-91. PubMed ID: 24398459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of nose-to-brain delivery of a P-glycoprotein (MDR1) substrate model drug (quinidine) in rats.
    Bors LA; Bajza Á; Mándoki M; Tasi BJ; Cserey G; Imre T; Szabó P; Erdő F
    Brain Res Bull; 2020 Jul; 160():65-73. PubMed ID: 32344126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful Prediction of Human Steady-State Unbound Brain-to-Plasma Concentration Ratio of P-gp Substrates Using the Proteomics-Informed Relative Expression Factor Approach.
    Storelli F; Anoshchenko O; Unadkat JD
    Clin Pharmacol Ther; 2021 Aug; 110(2):432-442. PubMed ID: 33675056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
    Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
    Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions.
    Nicolas JM; Chanteux H; Nicolaï J; Brouta F; Viot D; Rosseels ML; Gillent E; Bonnaillie P; Mathy FX; Long J; Helmer E
    Eur J Pharm Sci; 2020 Jan; 142():105122. PubMed ID: 31678424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios.
    Sato S; Matsumiya K; Tohyama K; Kosugi Y
    AAPS J; 2021 Jun; 23(4):81. PubMed ID: 34085128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
    Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
    Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
    Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
    Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios.
    Kalvass JC; Maurer TS; Pollack GM
    Drug Metab Dispos; 2007 Apr; 35(4):660-6. PubMed ID: 17237155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization.
    Jain R; Majumdar S; Nashed Y; Pal D; Mitra AK
    Mol Pharm; 2004; 1(4):290-9. PubMed ID: 15981588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats.
    O'Brien FE; Clarke G; Fitzgerald P; Dinan TG; Griffin BT; Cryan JF
    Br J Pharmacol; 2012 Jun; 166(4):1333-43. PubMed ID: 22250926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine.
    Duvvuri S; Gandhi MD; Mitra AK
    Curr Eye Res; 2003 Dec; 27(6):345-53. PubMed ID: 14704918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
    Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
    J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid.
    Karbownik A; Sobańska K; Płotek W; Grabowski T; Klupczynska A; Plewa S; Grześkowiak E; Szałek E
    Invest New Drugs; 2020 Jun; 38(3):574-583. PubMed ID: 31177402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
    Kreisl WC; Bhatia R; Morse CL; Woock AE; Zoghbi SS; Shetty HU; Pike VW; Innis RB
    J Nucl Med; 2015 Jan; 56(1):82-7. PubMed ID: 25500831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds.
    Dagenais C; Zong J; Ducharme J; Pollack GM
    Pharm Res; 2001 Jul; 18(7):957-63. PubMed ID: 11496955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Practical Perspective on the Evaluation of Small Molecule CNS Penetration in Drug Discovery.
    Huang L; Wells MC; Zhao Z
    Drug Metab Lett; 2019; 13(2):78-94. PubMed ID: 30854983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic Modeling of (
    García-Varela L; García DV; Kakiuchi T; Ohba H; Nishiyama S; Tago T; Elsinga PH; Tsukada H; Colabufo NA; Dierckx RAJO; van Waarde A; Toyohara J; Boellaard R; Luurtsema G
    Mol Pharm; 2021 Jan; 18(1):416-428. PubMed ID: 33315404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CSF as a surrogate for assessing CNS exposure: an industrial perspective.
    Lin JH
    Curr Drug Metab; 2008 Jan; 9(1):46-59. PubMed ID: 18220571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
    Elsby R; Surry DD; Smith VN; Gray AJ
    Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.